Drug for Erectile Dysfunction and Pulmonary Hypertension Improves Heart Function in Children and Young Adults With Single Ventricle Heart Disease
PHILADELPHIA, Nov. 17 /PRNewswire-USNewswire/ — Heart function significantly improved in children and young adults with single ventricle congenital heart disease who have had the Fontan operation following treatment with sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, say researchers from The Children’s Hospital of Philadelphia.
Single ventricle defects are a collection of cardiac malformations that impair the heart’s ability to pump blood. Examples include: tricuspid atresia, pulmonary atresia/intact ventricular septum and hypoplastic left heart syndrome.
The Fontan operation is a procedure that redirects systemic venous blood directly to the pulmonary arteries, bypassing the heart. It is the third surgery in a staged palliation for single ventricle heart defects.
Researchers hypothesized that sildenafil may help cardiac performance by directly improving the squeeze of the heart muscle and by allowing for better filling of the heart.
In this study, researchers randomized 28 children and young adults who had undergone the Fontan operation to receive placebo or sildenafil three times a day for 6 weeks. After a 6 week break, subjects were switched to the opposite treatment course. The researchers found significant improvement in heart performance during treatment with sildenafil.
“The enhanced heart performance may improve exercise performance and quality of life in these children and young adults,” said David J. Goldberg, M.D., pediatric cardiologist at The Children’s Hospital of Philadelphia, who presented the abstract today at the American Heart Association Scientific Sessions in Orlando, Fla.
Grants from The Mark H. and Blanche M. Harrington Foundation and from Big Hearts to Little Hearts provided funding for this study.
About The Children’s Hospital of Philadelphia: The Children’s Hospital of Philadelphia was founded in 1855 as the nation’s first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children’s Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking second in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 441-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.
Contact: Joey McCool Ryan (267) 426-6070 McCool@email.chop.edu
SOURCE The Children’s Hospital of Philadelphia